Elsevier

Archives of Gerontology and Geriatrics

Volume 51, Issue 3, November–December 2010, Pages e125-e128
Archives of Gerontology and Geriatrics

Tolcapone improves sleep in patients with advanced Parkinson's disease (PD)

https://doi.org/10.1016/j.archger.2010.03.008Get rights and content

Abstract

Efficacy of the long-acting catechol-O-methyltransferase (COMT)-inhibitor, tolcapone on sleep quality was studied in 61 patients with advanced PD in a prospective open-label multicenter non-interventional trial. Main outcome measures were the PD sleep scale (PDSS). Further outcome measures were global clinical impression of change (GCI-C), daily off-time, activities of daily living (UPDRS part II), quality of life (EuroQoL-5D), Epworth sleepiness scale (ESS) and adverse events reports. All efficiency and safety parameters were assessed 4 weeks after the switch to tolcapone and compared to baseline. The mean ± S.D. daily dose of tolcapone was 294.2 ± 36.9 mg/day at the final assessment. The mean PDSS scores significantly improved from 21.6 ± 8.1 at baseline to 16.3 ± 7.7 at final assessment (p < 0.0001). Consistently, daytime sleepiness was significantly reduced as reflected by lower scores on the ESS (p = 0.0057). Further efficacy parameters including GCI-C, daily off-time, activities of daily living, and quality of life were also significantly improved. Tolcapone was in general well tolerated and safe. This observational study provides first evidence that tolcapone improves sleep quality and reduces daytime sleepiness in patients suffering from advanced PD.

Introduction

The majority of patients with PD suffers from sleep disorders (Tandberg et al., 1998, Poewe and Hogl, 2000, Garcia-Borreguero et al., 2003, Comella, 2007). Disturbance of sleep in PD can be caused by various factors including primary sleep-wake dysregulation, symptoms of PD, medication-induced insomnia and effects of co-morbid conditions (Comella, 2007). The most common night-time sleep complaint is frequent nocturnal awakening (Factor et al., 1990). A further feature closely related to sleep disturbance is daytime sleepiness, which is often induced by medication but is also related to night-time sleep-deprivation (Rye, 2006, Comella, 2007).

Although sleep disturbances have a significant impact on quality of life in patients with PD (Scaravilli et al., 2003, Martinez-Martin et al., 2004), only few trials have specifically assessed the medical management of nocturnal problems in PD (Poewe and Seppi, 2008). Long-acting dopamine agonists have been shown to improve sleep (Chaudhuri et al., 2001, Poewe et al., 2007), but side effects are more frequent compared to levodopa, particularly in elderly patients (Poewe, 2003). Controlled release preparations of levodopa have been reported to relieve night-time problems in PD (Pahwa et al., 1993, Stocchi et al., 1998), but improvement of nocturnal disability was not superior with slow-release levodopa compared to standard preparations in a double-blind study (The U.K. Madopar CR Study Group, 1989).

Due to the limited duration of levodopa effects, the second half of the night is particularly critical for hypodopaminergic fluctuations (Poewe and Seppi, 2008). Tolcapone is an inhibitor of COMT providing increased bio-availability and longer plasma half-life of levodopa (Jorga et al., 1998). Although co-administration of tolcapone at bed-time should result in a longer nocturnal maintenance of therapeutic plasma-levels of levodopa and thus overcome the above mentioned limitations of levodopa use during night-time, there are no data available on the effects of tolcapone on sleep quality in PD. The present prospective open-label multicenter non-interventional trial, therefore, investigates the effects of tolcapone on sleep quality in PD assessing the PDSS before and after treatment with tolcapone.

Section snippets

Study design and patients

The present prospective open-label multicenter non-interventional trial was conducted in Germany from July 2008 to February 2009. 21 centers (mainly physicians in private practice) participated, with a total of 61 patients with PD who had not responded to or did not tolerate entacapone. Eligible individuals were men or women, aged 30–80 years old, with a diagnosis of idiopathic PD responsive to levodopa treatment, Hoehn & Yahr stage II-IV (Fahn et al., 1987) and were on stable medication for at

Demographics and baseline characteristics

Documentation forms of 61 patients: 22 women (36%) and 39 men (64%) from 21 centers were available for evaluation. Demographical data and baseline characteristics are summarized in Table 1. Mean Hoehn & Yahr stage was 2.9 ± 0.9 with most patients (36%) in stage III. All patients were regularly taking levodopa (mean ± S.D. daily dose: 639 ± 276 mg), 36 patients were on slow-release levodopa (in 29 patients, slow-release levodopa was given once only as bed-time medication). 86.9% of patients experienced

Discussion

In this study, tolcapone was shown to improve quality of sleep in patients with advanced PD. Sub-analysis of different items of the PDSS suggests that reduction of nocturnal akinesia was the key factor responsible for this effect. It is important to note that improvements were achieved in patients who already underwent optimized levodopa treatment including slow-release levodopa and/or the COMT-inhibitor entacapone in the majority of subjects.

Conflict of interest statement

Georg Ebersbach received honoraries for presentations and advisory board activities from Axxonis Pharma, Boehringer Ingelheim Pharma, Cephalon, Desitin Pharma, GlaxoSmithKline, MEDA, Novartis, Orion, und Schwarz Pharma (UCB).

Kirsten Hahn received honoraries for presentations from Novartis.

Michael Lorrain received honoraries for presentations and advisory board activities from Boehringer, Solvay, Cephalon, Meda, Orion, Eisai, Trommsdorf, GSK, UCB-Schwarz, Temmler, Serono-Merck, Novartis.

Acknowledgements

The statistical support of med:unit GmbH, Köln is gratefully acknowledged. This study was supported by a research grant of MEDA Pharmaceuticals Germany GmbH, Bad Homburg, Germany.

References (39)

  • C.L. Comella et al.

    Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy

    Neurology

    (2005)
  • S.A. Factor et al.

    Sleep disorders and sleep effect in Parkinson's disease

    Mov. Disord.

    (1990)
  • S.A. Factor et al.

    Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease

    Clin. Neuropharmacol.

    (2001)
  • S. Fahn et al.

    The Unified Parkinson's Disease Rating Scale

  • S. Frucht et al.

    Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

    Neurology

    (1999)
  • R.A. Hauser et al.

    Pramipexole-induced somnolence and episodes of daytime sleep

    Mov. Disord.

    (2000)
  • B. Hogl et al.

    The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease

    Neuropsychopharmacology

    (2003)
  • E.N. Jansen et al.

    Madopar HBS in nocturnal symptoms of Parkinson's disease

    Adv. Neurol.

    (1990)
  • M.W. Johns

    A new method for measuring daytime sleepiness: the Epworth sleepiness scale

    Sleep

    (1991)
  • Cited by (11)

    • Nonmotor Fluctuations in Parkinson's Disease

      2017, International Review of Neurobiology
      Citation Excerpt :

      However, the novel MAO-B inhibitor safinamide (with additional antiglutamatergic actions) was shown to improve not only motor complications in advanced PD but also ameliorate depression in a controlled clinical trial (Borgohain et al., 2014). The central acting COMT inhibitor tolcapone (Ceravolo et al., 2002; Gerlach, Ukai, Ozawa, & Riederer, 2002) is reported to be effective in reducing the motor wearing-Off phenomenon (Baas et al., 1997; Kurth et al., 1997; Rajput, Martin, Saint-Hilaire, Dorflinger, & Pedder, 1997) but also provides positive effects in several NMS, particularly antidepressive effects (Antonini et al., 2008; Ebersbach, Hahn, Lorrain, & Storch, 2010; Muller & TANIMOS Study Investigators, 2014). No data on NMF are available.

    • Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis

      2016, Parkinsonism and Related Disorders
      Citation Excerpt :

      Additionally, a large randomized placebo-controlled trial suggests that pimavaserin may improve nighttime sleep in PD patients with psychosis [53], while nortriptyline, but not paroxetine, may improve sleep quality in PD patients with clinical depression [54]. In an open-label study, tolcapone improved sleep quality [49], while the results of a retrospective study suggest that clozapine may improve sleep disturbances in PD patients [50]. Regarding the treatment of RBD, clonazepam is usually used as the first line [61].

    • The catechol-O-methyltransferase inhibitor, tolcapone, increases the bioavailability of unmethylated (-)-epigallocatechin-3-gallate in mice

      2015, Journal of Functional Foods
      Citation Excerpt :

      TOL produced consistently greater inhibitory effects when combined with EGCG compared to entacapone. Although initial clinical studies reported that TOL could induce liver toxicity, subsequent clinical studies have not reported additional cases of hepatotoxicity (Ebersbach, Hahn, Lorrain, & Storch, 2010; Lees, Ratziu, Tolosa, & Oertel, 2007; Lew & Kricorian, 2007; Olanow, 2000). Additional analysis of these data has concluded that the risk of hepatotoxic events related to TOL use are small and confined to older (>60 years old) subjects (Olanow & Watkins, 2007; Watkins, 2000).

    View all citing articles on Scopus
    View full text